Any current/future new fundraising through debt or equity?

No specific mention of any current or future fundraising through debt or equity in the document. The company plans to fund the ₹650-700 crore capacity addition/project entirely through internal accruals. Discussions indicate continued investments funded from internal resources rather than external fundraising. No announcements or hints about issuing new equity or taking on debt were made during the call.

Any current/future capex/capital investment/strategic investment?

Divi's Laboratories is planning a long-term supply agreement with an MNC supported by a capacity addition with an investment of ₹650 to ₹700 crores, funded from internal accruals. The proposed ₹650-700 crore facility is expected to be operational by January 2027. Unit III facility near Kakinada is progressing well with phase-wise production starting in FY 2024-25. Total capex guidance for FY 25 is around ₹1,500 to ₹1,600 crores, including balance spend of about ₹800 crores from Phase I and another ₹700 crores planned. Phase II capex will commence after commercializing Phase I. The ₹700 crore d

Future growth expectations in sales/revenue/volumes?

Divi's aims for consistent double-digit year-on-year growth in sales and revenue going forward. Volume growth is expected to support growth despite continued generic price erosion. Investment in new technologies and capacity expansions (₹1,500 crores capex for FY25 and beyond) will enable scaling up and future revenue increase. Growth engines include generics, custom synthesis (CS), contrast media, new product pipelines, and peptide projects. Custom synthesis segment and new projects in clinical phases are expected to fuel future growth. Generic volumes continue to increase steadily,

Future growth expectations in earnings/operating earnings/profits/EPS?

Divi's Laboratories expects continued double-digit sales growth year-on-year, driven by both generic and Custom Synthesis (CS) businesses. Generic business volume growth remains strong despite ongoing pricing pressure; future generics like Ticagrelor, Lacosamide, and Brivaracetam are expected to contribute from FY26-27 onwards. CS segment growth is supported by multiple new projects in various clinical phases, with steady value realization from existing projects and expansion in peptide opportunities. New long-term supply agreements and capacity additions (₹650-700 crores investment) will supp

Current/ Expected Orderbook/ Pending Orders?

Divi's Laboratories has experienced a substantial increase in inquiries for Custom Synthesis (CS) projects, including both existing clients and new large MNCs as well as small and mid-tier biotech companies. The inquiry increase is described as "phenomenal," with projects in various phases (Phase I to Phase III), reflecting strong demand. The timeline for converted contracts from RFPs to revenue generation can vary, typically ranging from 2-3 years up to 5-7 years depending on the project phase and regulatory approvals. Divi's is actively engaged with several multinationals with products in Ph

Divi's Lab.Q4 FY24Pharmaceuticals & Biotechnology

Divi's Lab. Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹9,664P/E: 86.1Market Cap: ₹2.6L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Divi's aims for consistent double-digit year-on-year growth in sales and revenue going forward.
Volume growth is expected to support growth despite continued generic price erosion.
Investment in new technologies and capacity expansions (₹1,500 crores capex for FY25 and beyond) will enable scaling up and future revenue increase.
Growth engines include generics, custom synthesis (CS), contrast media, new product pipelines, and peptide projects.
Custom synthesis segment and new projects in clinical phases are expected to fuel future growth.
Generic volumes continue to increase steadily, with new generics like Ticagrelor, Lacosamide, and Brivaracetam expected to contribute from FY26-27 onward.
Completion and commercialization of large-scale projects (e.g., ₹650-700 crores capacity addition) anticipated around 2027 will drive top-line growth.
The company expects to maintain or grow market share in both generics and CS segments despite pricing pressures.

Margin guidance

Category 3

Divi's Laboratories expects continued double-digit sales growth year-on-year, driven by both generic and Custom Synthesis (CS) businesses.
Generic business volume growth remains strong despite ongoing pricing pressure; future generics like Ticagrelor, Lacosamide, and Brivaracetam are expected to contribute from FY26-27 onwards.
CS segment growth is supported by multiple new projects in various clinical phases, with steady value realization from existing projects and expansion in peptide opportunities.
New long-term supply agreements and capacity additions (₹650-700 crores investment) will support growth.
Price erosion in generics is expected to stabilize over 1-2 years, improving margins gradually.
Kakinada facility phase-wise commercialization starting H2 FY25 will add capacity and support revenue/earnings growth.
Margin improvements expected from operational efficiencies and backward integration advantages.
Overall, the outlook for profits/EPS is positive with growth engines maturing and new product launches.

See what Divi's Lab. management said on margin guidance — free account, 30 seconds.

Fundraise plans

No specific mention of any current or future fundraising through debt or equity in the document.
The company plans to fund the ₹650-700 crore capacity addition/project entirely through internal accruals.
Discussions indicate continued investments funded from internal resources rather than external fundraising.
No announcements or hints about issuing new equity or taking on debt were made during the call.

Order book

Yes

Divi's Laboratories has experienced a substantial increase in inquiries for Custom Synthesis (CS) projects, including both existing clients and new large MNCs as well as small and mid-tier biotech companies.
The inquiry increase is described as "phenomenal," with projects in various phases (Phase I to Phase III), reflecting strong demand.
The timeline for converted contracts from RFPs to revenue generation can vary, typically ranging from 2-3 years up to 5-7 years depending on the project phase and regulatory approvals.
Divi's is actively engaged with several multinationals with products in Phase III and fast track, indicating a robust order book in the CS segment.
Specific quantification of order book or pending orders is not disclosed due to confidentiality agreements.
The long-term agreements with multinational companies are expected to lead to more opportunities and tie-ups going forward.

See what Divi's Lab. management said on order book — free account, 30 seconds.

Capex plans

Yes

Divi's Laboratories is planning a long-term supply agreement with an MNC supported by a capacity addition with an investment of ₹650 to ₹700 crores, funded from internal accruals.
The proposed ₹650-700 crore facility is expected to be operational by January 2027.
Unit III facility near Kakinada is progressing well with phase-wise production starting in FY 2024-25.
Total capex guidance for FY 25 is around ₹1,500 to ₹1,600 crores, including balance spend of about ₹800 crores from Phase I and another ₹700 crores planned.
Phase II capex will commence after commercializing Phase I.
The ₹700 crore dedicated project has a long gestation (~2.5 years) due to early-stage development and regulatory validations.
The company is investing in specialized technologies (flow chemistry, mechanochemistry, etc.) to improve cost efficiency and green chemistry adherence.

Track Divi's Lab. — get its next earnings analysis in your feed

How does Divi's Lab. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisDivi's Lab.

Rev 3Mar 3

See where Divi's Lab. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Divi's Lab. rank in Pharmaceuticals & Biotechnology?

Compare Divi's Lab. against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Divi's Lab.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Torrent Pharmaceuticals Ltd vs Laurus Labs Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Divi's Lab. Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Divi's Lab. rank in Pharmaceuticals & Biotechnology?

Continue your research

What Divi's Lab.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season